Phoenix winnonlin 6

Manufactured by Pharsight

Sourced in United States, Sao Tome and Principe

Phoenix WinNonlin 6.3 is a software application for pharmacokinetic and pharmacodynamic analysis. It provides tools for data visualization, model fitting, and reporting of clinical trial data.

Automatically generated - may contain errors

Lab products found in correlation

Sas 9, by SAS Institute (2 mentions) Spss statistics 21, by IBM (2 mentions) Winnonlin 6, by Pharsight (1 mentions) Spss statistics version 19, by IBM (1 mentions) Jmp statistical software, by SAS Institute (1 mentions) Triple quad 5500, by Thermo Fisher Scientific (1 mentions) Statistical package for the social sciences software version 19, by IBM (1 mentions) Nonmem 7, by ICON Development Solutions (1 mentions) Analyst tf 1, by AB Sciex (1 mentions) Peakview1, by AB Sciex (1 mentions) Masslynx 4, by Waters Corporation (1 mentions) Metabolitepilot 1, by AB Sciex (1 mentions) Prism 9, by GraphPad (1 mentions) Magellan tracker v7, by Tecan (1 mentions) Nonmem, by ICON Development Solutions (1 mentions) H class uplc, by Waters Corporation (1 mentions) Stata ic version 14, by StataCorp (1 mentions) Systat 13, by Grafiti LLC (1 mentions) Sas version 9, by SAS Institute (1 mentions) Prism 3, by GraphPad (1 mentions)

Close spelling variants of this product

WinNonlin (378 citations) Phoenix WinNonlin (248 citations) WinNonlin 6.3 (61 citations) Phoenix WinNonlin version 6.3 (51 citations) Phoenix 64 WinNonlin 6.3 (5 citations) Phoenix™ WinNonlin® Professional Version 6.3 (4 citations) Phoenix WinNonlin software version 6.3 (3 citations) WinNonlin Phoenix Version 6.2.1 or higher (2 citations) Phoenix WinNonlin software 6·1 (2 citations)

94 protocols using phoenix winnonlin 6

Plasma Pharmacokinetics of CS and DCF

Check if the same lab product or an alternative is used in the 5 most similar protocols

The plasma concentration-time curve was constructed for each calf using the software program (Phoenix WinNonLin 6.3, Pharsight, St. Louis, MO, U.S.A.). Individual plasma concentration-time curves and Akaike Information Criteria
(AIC) were examined for evaluation of the pharmacokinetics of CS and DCF, as previously described [52 (link)]. The pharmacokinetic variables were analyzed based on a two-compartment model. The peak
plasma concentration (C_max), and time elapsed to reach peak plasma concentration (T_max) were determined based on the plasma concentration-time curve for each calf. Other parameters were calculated using the
pharmacokinetic software program (Phoenix WinNonLin 6.3, Pharsight).

ALTAN F., UNEY K., ER A., CETIN G., DIK B., YAZAR E, & ELMAS M. (2017). Pharmacokinetics of ceftiofur in healthy and lipopolysaccharide-induced endotoxemic newborn calves treated with single and combined therapy. The Journal of Veterinary Medical Science, 79(7), 1245-1252.

+ Open protocol

+ Expand

Noncompartmental Pharmacokinetic Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols

A standard noncompartmental analysis was performed for each individual cefoxitin plasma concentration-time profile using Phoenix WinNonlin 6.1 software (Pharsight, Mountain View, CA). Terminal half-life, area under the concentration-time curve from time zero to infinity (AUC, calculated by linear trapezoidal method), volume of distribution at steady state (V_ss), and systemic clearance (CL) were calculated. Individual plasma concentration-time profiles were evaluated using one compartment model. Plasma concentration at the time of wound closure was determined from the fitted profiles, and the ratio of tissue to plasma concentration was calculated for all patients.

Brunetti L., Kagan L., Forrester G., Aleksunes L.M., Lin H., Buyske S, & Nahass R.G. (2015). Cefoxitin plasma and subcutaneous adipose tissue concentration in patients undergoing sleeve gastrectomy. Clinical therapeutics, 38(1), 204-210.

+ Open protocol

+ Expand

Pharmacokinetic Analysis of Preclinical Data

Check if the same lab product or an alternative is used in the 5 most similar protocols

Concentration versus time data from mice, rats, and cynomolgus monkeys were calculated by non-compartmental analysis using Phoenix WinNonlin 6.1 (Pharsight Corporation, Mountain View, CA, USA). Clearances, volumes of distribution, maximum concentration (C_max), and area under the plasma concentration-time curves from zero to the last measurable point (AUC_last) were determined. The elimination rate constant (k_e) was estimated from the slope of the best-fit line determined by linear regression analysis of a log-transformed concentration-time curve. The elimination half-life (t_1/2) was then calculated by the equation t_1/2= ln(2)/k_e. Clearance was calculated as the dose divided by the AUC from time zero to infinity (AUC_inf).

Lee W.S., Shim S.R., Lee S.Y., Yoo J.S, & Cho S.K. (2018). Preclinical pharmacokinetics, interspecies scaling, and pharmacokinetics of a Phase I clinical trial of TTAC-0001, a fully human monoclonal antibody against vascular endothelial growth factor 2. Drug Design, Development and Therapy, 12, 495-504.

+ Open protocol

+ Expand

Pharmacokinetics of Nebivolol and Metabolite

Check if the same lab product or an alternative is used in the 5 most similar protocols

Non-compartmental pharmacokinetic (PK) analysis was employed to determine the pharmacokinetic parameters of nebivolol and its hydroxylated active metabolite (4-OH-nebivolol). The analytical method for nebivolol determination was not enantioselective. The maximum plasma concentration (C_max, ng/ml) and the time to reach the peak concentration (t_max, h) were obtained directly by visual inspection of each subject’s plasma concentration-time profile. The area under the concentration-time curve (AUC_0-t) was estimated by integration using the trapezoidal rule from time zero to the last measurable concentration at time t. The area was extrapolated to infinity (AUC_0-∞) by addition of C_t/k_el to AUC_0-t where C_t is the last quantifiable drug concentration and k_el is the elimination rate constant. The pharmacokinetic analysis was carried out using Phoenix WinNonlin 6.1 (Pharsight, USA).

BRICIU C., NEAG M., MUNTEAN D., BOCSAN C., BUZOIANU A., ANTONESCU O., GHELDIU A.M., ACHIM M., POPA A, & VLASE L. (2015). Phenotypic differences in nebivolol metabolism and bioavailability in healthy volunteers. Clujul Medical, 88(2), 208-213.

+ Open protocol

+ Expand

Phase I Study of CKD-516 Pharmacokinetics

Check if the same lab product or an alternative is used in the 5 most similar protocols

Safety and tolerability were measured by adverse events (AEs), vital sign, body weight, electrocardiogram (ECG), and laboratory tests. Safety was assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) ver. 4.02. PK parameters of CKD-516 and S-516 were calculated using the noncompartmental method with Phoenix WinNonlin 6.1 (Pharsight, Mountain View, CA). The pharmacokinetic linearity was assessed by linear regressions between dose and C_max or AUC_last and between log-transformed dose and log-transformed C_max or log-transformed AUC_last. Efficacy was measured using Response Evaluation Criteria in Solid Tumor (RECIST) ver. 1.1. Tumor responses were assessed after the first cycle or earlier in patients with suspected progression.

Oh D.Y., Kim T.M., Han S.W., Shin D.Y., Lee Y.G., Lee K.W., Kim J.H., Kim T.Y., Jang I.J., Lee J.S, & Bang Y.J. (2015). Phase I Study of CKD-516, a Novel Vascular Disrupting Agent, in Patients with Advanced Solid Tumors. Cancer Research and Treatment : Official Journal of Korean Cancer Association, 48(1), 28-36.

+ Open protocol

+ Expand

Noncompartmental Pharmacokinetic Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols

The PK parameters for the probe substrates were calculated for each subject by a noncompartmental analysis using Phoenix WinNonlin 6.1 software (Pharsight, Mountain View, CA). The plasma C_max and time to reach C_max (t_max) were obtained directly from experimental observations. The AUC from time zero to the last measureable time point (AUC_0–t) was calculated by a linear trapezoidal method using the actual elapsed time. The AUC from time zero to infinity (AUC_∞) was calculated by the following equation: AUC_∞ = AUC_0–t+C_t/k_el, where C_t is the plasma concentration of the probe substrate at the last measureable time point and k_el is the elimination rate constant.

Narushima K., Maeda H., Shiramoto M., Endo Y., Ohtsuka S., Nakamura H., Nagata Y., Uchimura T., Kannami A., Shimazaki R., Fukagawa M, & Akizawa T. (2018). Assessment of CYP‐Mediated Drug Interactions for Evocalcet, a New Calcimimetic Agent, Based on In Vitro Investigations and a Cocktail Study in Humans. Clinical and Translational Science, 12(1), 20-27.

+ Open protocol

+ Expand

Pharmacokinetics of Amifampridine and Metabolite

Check if the same lab product or an alternative is used in the 5 most similar protocols

Plasma concentration-time data were used to calculate PK parameters for amifampridine and the 3-N-acetyl metabolite using noncompartmental analysis (Phoenix WinNonlin 6.1; Pharsight Corporation, Cary, NC). The values for C_max and T_max were obtained directly from plasma-time concentration data by inspection without interpolation. The values for AUC_0-t were calculated by the linear trapezoidal rule. The AUC_0-4h values for each multiple dosing interval in Part 2 were calculated using a 0–4 h reference time interval (not clock time) for each of the four doses on Days 1 and 3. The apparent t½ was calculated by 0.693/λz, where the terminal elimination rate constant λz was determined by log-linear regression of the terminal plasma concentrations. The AUC_0-∞ was calculated by AUC_0-t + Ct/λz, where Ct is the last measurable plasma concentration for measured drug or metabolite. The apparent oral clearance CL/F was calculated by dose/AUC_0-∞, where F represents the unknown fraction of absorbed drug. The apparent oral volume of distribution V_dz/F was calculated based on the terminal elimination rate constant by (CL/F) · 1/λz. The apparent oral volume of distribution at steady state V_dss/F was calculated as MRT_0-∞ · CL/F, where MRT_0-∞ is the mean residence time extrapolated from time 0 to infinity.

Haroldsen P.E., Garovoy M.R., Musson D.G., Zhou H., Tsuruda L., Hanson B, & O’Neill C.A. (2014). Genetic variation in aryl N-acetyltransferase results in significant differences in the pharmacokinetic and safety profiles of amifampridine (3,4-diaminopyridine) phosphate. Pharmacology Research & Perspectives, 3(1), e00099.

+ Open protocol

+ Expand

Pharmacokinetics of Tamoxifen and Metabolites

Check if the same lab product or an alternative is used in the 5 most similar protocols

Blood samples (4 mL; lithium-heparin) for the measurement of tamoxifen and its main metabolites were collected just before and at 0.5, 1, 1.5, 2, 4, 6, 8, 12 and 24 h after administration of tamoxifen. Plasma was isolated by centrifugation of the samples for 10 min at 2500g and was stored at −70° C until the analysis. The measurement of tamoxifen and its main metabolites in plasma was performed using a validated ultra-performance liquid chromatography (UPLC)–tandem mass spectrometry (MS/MS) assay, as described elsewhere [18 (link)].
Individual pharmacokinetic parameters, including the trough concentration (C_trough) and maximum concentration (C_max), were determined, and the area under the plasma concentration–time curve from time zero to 24 h (AUC_0–24) was calculated by noncompartmental analysis using Phoenix WinNonlin 6.1 (Pharsight Corporation, Mountain View, CA, USA). The estimated parameters of patients who used 40 mg tamoxifen were corrected to 20 mg. The metabolic ratios were computed as AUC_0–24_metabolite/AUC_0–24_tamoxifen.

Binkhorst L., Bannink M., de Bruijn P., Ruit J., Droogendijk H., van Alphen R.J., den Boer T.D., Lam M.H., Jager A., van Gelder T, & Mathijssen R.H. (2015). Augmentation of Endoxifen Exposure in Tamoxifen-Treated Women Following SSRI Switch. Clinical Pharmacokinetics, 55, 249-255.

+ Open protocol

+ Expand

Pharmacokinetic Analysis of Amoxicillin

Check if the same lab product or an alternative is used in the 5 most similar protocols

Pharmacokinetic analysis of the data was performed using non-compartmental analysis by the software data package Phoenix WinNonlin 6.1 (Pharsight Corporation, Mountain View, CA, USA). The parameters determined include λz (the slope of the terminal elimination phase of the time-concentration curve), t_1/2λ (elimination or terminal half-life), C_max (maximum plasma concentration), T_max (time to reach C_max), AUC_INF (area under the plasma concentration–time curve from time zero to infinity), AUMC_INF (area under the moment curve), MRT (mean residence time). All of these parameters were compared between the different products by one way analysis of variance (ANOVA) using statistical software SPSS 17.0 (SPSS Inc., Chicago, IL, USA). All results were presented as mean ± SD and a P-value of 0.05 was set as the threshold for differences to be considered statistically significant. The relative bioavailability (F) of AMO was calculated by the method of corresponding areas, which entails comparison of the total areas under the plasma concentration-time curves (AUC) obtained after p.o and i.m. administration: F = AUC_p.o./AUC_i.m..

Dai C., Zhao T., Yang X., Xiao X., Velkov T, & Tang S. (2017). Pharmacokinetics and relative bioavailability of an oral amoxicillin-apramycin combination in pigs. PLoS ONE, 12(4), e0176149.

+ Open protocol

+ Expand

Donepezil Pharmacokinetics and Dose Linearity

Check if the same lab product or an alternative is used in the 5 most similar protocols

The plasma concentration–time profiles of donepezil in the subjects were analyzed by using a noncompartmental method and WinNonlin 6.1 (Pharsight Corporation, Princeton, NJ, USA). All analyses were made by using actual times of sampling. The C_max and t_max were determined from the observed values. The terminal elimination rate constant (λz) was estimated by linear regression of the terminal log-linear portion of the plasma concentration–time curves. The area under the time–concentration curve (AUC) from time 0 to the last measurable time (AUC_last) was calculated by the trapezoidal rule, and the AUC extrapolated to infinity (AUC_inf) was obtained as follows:

{AUC}_{inf} = {AUC}_{last} + C_{last} / λ z

for which C_last is the last quantifiable concentration.
The t_1/2β was calculated for each participant as follows:

t_{1 / 2 β} = \ln (2) / λ z

All statistical analyses were performed by using SAS 9.3 (SAS Korea, Seoul, Republic of Korea) and Phoenix WinNonlin 6.1 (Pharsight Corporation). Demographic data and pharmacokinetic parameters were summarized by using descriptive statistics. Dose linearity was investigated by using the Kruskal–Wallis test to evaluate the dose-normalized C_max and AUC_inf values.

Kim Y.H., Choi H.Y., Lim H.S., Lee S.H., Jeon H.S., Hong D., Kim S.S., Choi Y.K, & Bae K.S. (2015). Single dose pharmacokinetics of the novel transdermal donepezil patch in healthy volunteers. Drug Design, Development and Therapy, 9, 1419-1426.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!